Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fluticasone propionate (CCI-187881), derived from fluticasone used to remedy asthma and allergic rhinitis, is a high affinity, selective GR (glucocorticoid receptor) agonist.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 45.00 | |
10 mg | In stock | $ 72.00 | |
25 mg | In stock | $ 126.00 | |
50 mg | In stock | $ 197.00 | |
100 mg | In stock | $ 286.00 | |
200 mg | In stock | $ 357.00 | |
500 mg | In stock | $ 590.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 76.00 |
Description | Fluticasone propionate (CCI-187881), derived from fluticasone used to remedy asthma and allergic rhinitis, is a high affinity, selective GR (glucocorticoid receptor) agonist. |
In vitro | Fluticasone propionate (1 pM) inhibits the constitutive and TGF-beta-induced expression of alpha-SMA in human lung myofibroblasts. Fluticasone propionate blocks the TNF-alpha-induced nuclear translocation of the pro-inflammatory transcription factor NF-kappaB in human lung myofibroblasts. [1] Fluticasone propionate inhibits in lung myofibroblasts, at a very early stage of differentiation, the activation of Janus kinase/STAT pathways induced by IL-13 (tyrosine kinase 2, STAT1, STAT3, STAT6, mitogen-activated protein kinase). Fluticasone propionate still displays a potential anti-inflammatory activity even if it only inhibits tyrosine kinase 2 phosphorylation in mildly or fully differentiated myofibroblastic cultures. Fluticasone propionate inhibits constitutive and TGF-beta-induced expression of alpha-smooth muscle actin, the main marker of myofibroblastic differentiation, both in very early and in mild differentiated myofibroblasts. Fluticasone propionate displays an additional powerful anti-inflammatory effect, decreasing nuclear translocation of NF-kappaB independent of the degree of myofibroblastic differentiation. [2] Fluticasone propionate inhibits allergen-induced T-cell proliferation, expression of IL-3, IL-5 and GM-CSF mRNA, and secretion of the corresponding proteins in a concentration-dependent fashion. Fluticasone propionate has the potential markedly to inhibit allergen-induced T-cell production of asthma-relevant cytokines. [3] |
In vivo | Fluticasone propionate administrated after induction of a severe heaves exacerbation results in complete resolution of clinical signs, normalization of pulmonary function tests, and significant decrease in bronchoalveolar lavage (BAL) neutrophilia in horse. [4] |
Synonyms | CCI-187881, Fluticasone propionate |
Molecular Weight | 500.57 |
Formula | C25H31F3O5S |
CAS No. | 80474-14-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (50 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Fluticasone (propionate) 80474-14-2 Endocrinology/Hormones Metabolism Microbiology/Virology Virus Protease Glucocorticoid Receptor Phospholipase Estrogen/progestogen Receptor Endogenous Metabolite Enterovirus CCI 187881 Fluticasone HEVs HEV HRVs perennial bronchial anti-inflammatory CCI187881 asthma Inhibitor HRV CCI-187881 Rhinovirus seasonal rhinitis allergic inhibit corticosteroid Fluticasone propionate Fluticasone Propionate inhibitor